Cargando…

The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function

New technologies may displace existing, higher‐value care under a fixed budget. Countries aim to curtail adoption of low‐value technologies, for example, by installing cost‐effectiveness thresholds. Our objective is to estimate the opportunity cost of hospital care to identify a threshold value for...

Descripción completa

Detalles Bibliográficos
Autores principales: Stadhouders, Niek, Koolman, Xander, van Dijk, Christel, Jeurissen, Patrick, Adang, Eddy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851736/
https://www.ncbi.nlm.nih.gov/pubmed/31469510
http://dx.doi.org/10.1002/hec.3946
_version_ 1783469674818699264
author Stadhouders, Niek
Koolman, Xander
van Dijk, Christel
Jeurissen, Patrick
Adang, Eddy
author_facet Stadhouders, Niek
Koolman, Xander
van Dijk, Christel
Jeurissen, Patrick
Adang, Eddy
author_sort Stadhouders, Niek
collection PubMed
description New technologies may displace existing, higher‐value care under a fixed budget. Countries aim to curtail adoption of low‐value technologies, for example, by installing cost‐effectiveness thresholds. Our objective is to estimate the opportunity cost of hospital care to identify a threshold value for the Netherlands. To this aim, we combine claims data, mortality data and quality of life questionnaires from 2012 to 2014 for 11,000 patient groups to obtain quality‐adjusted life‐year (QALY) outcomes and spending. Using a fixed effects translog model, we estimate that a 1% increase in hospital spending on average increases QALY outcomes by 0.2%. This implies a threshold of €73,600 per QALY, with 95% confidence intervals ranging from €53,000 to €94,000 per QALY. The results stipulate that new technologies with incremental cost effectiveness ratios exceeding the Dutch upper reference value of €80,000 may indeed displace more valuable care.
format Online
Article
Text
id pubmed-6851736
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68517362019-11-18 The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function Stadhouders, Niek Koolman, Xander van Dijk, Christel Jeurissen, Patrick Adang, Eddy Health Econ Research Articles New technologies may displace existing, higher‐value care under a fixed budget. Countries aim to curtail adoption of low‐value technologies, for example, by installing cost‐effectiveness thresholds. Our objective is to estimate the opportunity cost of hospital care to identify a threshold value for the Netherlands. To this aim, we combine claims data, mortality data and quality of life questionnaires from 2012 to 2014 for 11,000 patient groups to obtain quality‐adjusted life‐year (QALY) outcomes and spending. Using a fixed effects translog model, we estimate that a 1% increase in hospital spending on average increases QALY outcomes by 0.2%. This implies a threshold of €73,600 per QALY, with 95% confidence intervals ranging from €53,000 to €94,000 per QALY. The results stipulate that new technologies with incremental cost effectiveness ratios exceeding the Dutch upper reference value of €80,000 may indeed displace more valuable care. John Wiley and Sons Inc. 2019-08-30 2019-11 /pmc/articles/PMC6851736/ /pubmed/31469510 http://dx.doi.org/10.1002/hec.3946 Text en © 2019 The Authors. Health Economics published by John Wiley & Sons, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Stadhouders, Niek
Koolman, Xander
van Dijk, Christel
Jeurissen, Patrick
Adang, Eddy
The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function
title The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function
title_full The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function
title_fullStr The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function
title_full_unstemmed The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function
title_short The marginal benefits of healthcare spending in the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function
title_sort marginal benefits of healthcare spending in the netherlands: estimating cost‐effectiveness thresholds using a translog production function
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851736/
https://www.ncbi.nlm.nih.gov/pubmed/31469510
http://dx.doi.org/10.1002/hec.3946
work_keys_str_mv AT stadhoudersniek themarginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction
AT koolmanxander themarginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction
AT vandijkchristel themarginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction
AT jeurissenpatrick themarginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction
AT adangeddy themarginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction
AT stadhoudersniek marginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction
AT koolmanxander marginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction
AT vandijkchristel marginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction
AT jeurissenpatrick marginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction
AT adangeddy marginalbenefitsofhealthcarespendinginthenetherlandsestimatingcosteffectivenessthresholdsusingatranslogproductionfunction